|
| The authors demonstrated in COVID-19-recovered individuals a robust CD4+ T cell response to naturally processed SARS-CoV-2 spike and nucleoprotein, including effector, helper, and memory T cells.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Using immunophenotyping, RNA sequencing and serum cytokine analysis, scientists analyzed serial samples from 207 SARS-CoV2-infected individuals with a range of disease severities over 12 weeks from symptom onset.
[Immunity] |
|
|
|
| To identify potent antiviral innate immune agonists, researchers screened a panel of 75 microbial ligands that activate diverse signaling pathways and identified cyclic dinucleotides, canonical STING agonists, as antiviral.
[Science Immunology] |
|
|
|
| Unlike recent single cell RNA-sequencing analyses indicating uniformly low mRNA expression of SARS-CoV-2 entry-related host molecules in all nasal epithelial cells, scientists showed that the protein levels were relatively high and their localizations were restricted to the apical side of multiciliated epithelial cells.
[Journal of Clinical Investigation] |
|
|
|
| Researchers constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike protein.
[Emerging Microbes & infections] |
|
|
|
| Investigators engineered the coat protein of the MS2 bacteriophage and generated nanoparticles displaying multiple copies of the SARS-CoV-2 spike protein.
[Communications Biology] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| LTβR‐agonist was assessed in vitro and in vivo. Induction of A3B and subsequent effects were analysed by RT‐qPCR, immunoblotting, ChIP, ICC, and mass‐spectrometry.
[Hepatology] |
|
|
|
| Scientists reported, using the pathogenic model of antiretroviral therapy-treated, SIV-infected rhesus macaques that sequential interleukin-21 and interferon alpha therapy generated terminally differentiated blood natural killer cells with potent human leukocyte antigen-E-restricted activity in response to SIV envelope peptides.
[Nature Communications] |
|
|
|
| The authors examined the function and mechanism of m6A mRNA modification and the YTH domain-containing protein YTHDF1in the innate immune response against bacterial pathogens in the intestine.
[Nucleic Acids Research] |
|
|
|
| A single immunization with 10μg modified mRNA-lipid nanoparticles protected most susceptible mice from mousepox, and booster vaccination increased the memory CD8 T cell pool providing full protection.
[Molecular Therapy] |
|
|
|
| Scientists showed that hemocytes are recruited to the midgut of Aedes aegypti mosquitoes in response to the dengue and Zika viruses.
[Frontiers in Immunology] |
|
|
|
| Utilizing an in vitro system, the authors identified that macrophages relied on nitric oxide (NO) for only half of their L-arginine-mediated host defenses and this L-arginine-mediated defense in the absence of NO was associated with enhanced macrophage numbers and viability.
[Frontiers in Immunology] |
|  |
|
|
|
| CD8+ T cell noncytotoxic antiviral responses have now been observed with other virus families but are mediated by different cytokines. Characterizing the protein structure of CD8+ T cell antiviral factor has been challenging despite many biologic, immunologic, and molecular studies.
[Microbiology and Molecular Biology Reviews] |
|
|
|
|
| Sanofi and GSK announced positive results from a Phase II clinical trial of their joint COVID-19 vaccine, saying it generated strong levels of neutralizing antibodies in recipients across all ages studied. The partners said a large international Phase III trial will begin in coming weeks.
[STAT News] |
|
|
|
| Veru, Inc. announced that it has enrolled the first patient in its Phase III clinical trial of sabizabulin, a novel, proprietary, oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties, to combat the effects of COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2.
[Veru, Inc.] |
|
|
|
| Oxford Immunotec announced that its T-SPOT® Discovery SARS-CoV-2 kit is being used for T cell testing in the UK COVID-19 Human Challenge Study, a national collaboration including the UK government, the NHS, academia and the private sector.
[Oxford Immunotec] |
|
|
|
|
| July 9 – 12, 2021
Vienna, Austria |
|
|
|
|
|
| | The Journal of Infectious Diseases – Arlington, Virginia, United States |
|
|
|
| | Kings’s College London – London, England, United Kingdom |
|
|
|
| | Trinity College Dublin – Dublin, Republic of Ireland |
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
